For adult patients with moderate to severe chronic plaque psoriasis (Ps) and adult patients with active psoriatic arthritis (PsA)

Targeting TNF-alpha in Ps and PsA

Overexpression of TNF-alpha, along with other cytokines, contributes to the inflammatory cycle seen in both conditions2-4

In Ps

Continuous dysregulated inflammatory signaling
contributes to epidermal thickening.5,6

photos of skin with moderate Ps and skin with epidermal thickening and TNF-alpha

In PsA

Elevated levels of TNF-alpha and other cytokines may
lead to inflammation and joint destruction.4,7,8

depiction of psoriatic arthritis and TNF-alpha and a radiographic image of joints with structural damage

The AAD recognizes the role of TNF-alpha in the pathophysiology of Ps and PsA5

American Academy of Dermatology logo

TNF-alpha is overexpressed in both the affected skin and serum of patients with Ps.5

TNF-alpha, IL-8, IL-6, IL-1, IL-10, and matrix metalloproteinases are present at high levels in the joint fluid of patients with early PsA.9

HUMIRA specifically targets and blocks TNF-alpha, a key driver of systemic inflammation, which can contribute to skin disease on the outside and joint damage on the inside.1

The relationship between these pharmacodynamic activities and the mechanism(s) by which HUMIRA exerts its clinical effects is unknown.1